<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748696</url>
  </required_header>
  <id_info>
    <org_study_id>06-API-04</org_study_id>
    <nct_id>NCT00748696</nct_id>
  </id_info>
  <brief_title>Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia</brief_title>
  <official_title>Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related sarcopenia is associated with increased morbidity, mortality, disability and&#xD;
      reduced resistance to metabolic stress. The aim of this study is to assess the effects of&#xD;
      resistance training, associated or not with oral nutritional supplements, on skeletal muscle&#xD;
      mass in sarcopenic subjects. This is a prospective randomised controlled single-centre study&#xD;
      that will last two years, three months for a participant.&#xD;
&#xD;
      200 healthy elderly (70-80 years old) subjects will be screened for sarcopenia by dual energy&#xD;
      X-ray absorptiometry. 128 sarcopenic subjects will be randomized into 4 groups:&#xD;
&#xD;
        -  group 1: controls&#xD;
&#xD;
        -  group 2: oral nutritional supplement (260 kcal and 20 g protein per day)&#xD;
&#xD;
        -  group 3: resistance training (3 times per week)&#xD;
&#xD;
        -  group 4: oral nutritional supplement + resistance training&#xD;
&#xD;
      Every subject will be assessed at the beginning and at the end of 12 weeks of intervention&#xD;
      on:&#xD;
&#xD;
        -  muscle mass (DXA)&#xD;
&#xD;
        -  muscle function (dynamometers)&#xD;
&#xD;
        -  hormonal (testosterone, GH, IGF-1, cortisol) and inflammatory (IL-6, TNF-alpha) profiles&#xD;
&#xD;
        -  food intake. Ten subjects in group 4 will undergo a muscle biopsy (quadriceps) before&#xD;
           and after the intervention in order to explore protein and mRNA levels of the mTOR&#xD;
           pathway, which may be involved in sarcopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related sarcopenia is a common situation defined by muscle mass and function loss in an&#xD;
      otherwise healthy elderly person. Epidemiological data from the USA show 49% of men and 72%&#xD;
      of women to suffer from sarcopenia. Few data is available on the French population.&#xD;
      Sarcopenia is associated with increased morbidity, mortality, disability and reduced&#xD;
      resistance to metabolic stress. Resistance training and nutrition are two non-pharmaceutical&#xD;
      methods that may be able to prevent several age-related condition.&#xD;
&#xD;
      The aim of this study is to assess the effects of resistance training, associated or not with&#xD;
      oral nutritional supplements, on skeletal muscle mass (expressed as skeletal muscle mass&#xD;
      index) in sarcopenic subjects. This is a prospective randomised controlled single-centre&#xD;
      study that will last two years, three months for a participant.&#xD;
&#xD;
      200 healthy elderly (70-80 years old) subjects will be screened for sarcopenia by dual energy&#xD;
      X-ray absorptiometry. 128 sarcopenic subjects will be randomized into 4 groups:&#xD;
&#xD;
        -  group 1: controls&#xD;
&#xD;
        -  group 2: oral nutritional supplement (260 kcal and 20 g protein per day)&#xD;
&#xD;
        -  group 3: resistance training (3 times per week)&#xD;
&#xD;
        -  group 4: oral nutritional supplement + resistance training&#xD;
&#xD;
      Every subject will be assessed at the beginning and at the end of 12 weeks of intervention&#xD;
      on:&#xD;
&#xD;
        -  muscle mass (DXA)&#xD;
&#xD;
        -  muscle function (dynamometers)&#xD;
&#xD;
        -  hormonal (testosterone, GH, IGF-1, cortisol) and inflammatory (IL-6, TNF-alpha) profiles&#xD;
&#xD;
        -  food intake. Ten subjects in group 4 will undergo a muscle biopsy (quadriceps) before&#xD;
           and after the intervention in order to explore protein and mRNA levels of the mTOR&#xD;
           pathway, which may be involved in sarcopenia.&#xD;
&#xD;
      We expect to show that sarcopenia can be improved by 12 weeks of resistance training and that&#xD;
      this improvement can be potentialized by oral nutritional supplements (with a stimulation of&#xD;
      the mTOR pathway), and that oral nutritional supplements alone will affect neither muscle&#xD;
      mass nor function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle mass (DXA)</measure>
    <time_frame>D0 and after 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle function (dynamometers), hormonal (testosterone, GH, IGF-1, cortisol) and inflammatory (IL-6, TNF-alpha) profiles, food intake, ± muscle biopsy.</measure>
    <time_frame>D0 and after 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient receiving oral nutrition supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>resistance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving resistance training and oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fortimel Extra®</intervention_name>
    <description>260kcal and 20g protein per day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>resistance training</intervention_name>
    <description>3 sessions of resistance training per week</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>combined treatment</intervention_name>
    <description>260kcal and 20g protein per day 3 sessions of resistance training per week</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 70 and 80 years&#xD;
&#xD;
          -  Stable weight (± 1 kg) during the last three months&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  Affiliated with the French Sécurité Sociale Non-inclusion criteria&#xD;
&#xD;
          -  Chronic cachectic condition: cancer, chronic respiratory failure, advanced organ&#xD;
             failure, hyperthyroidism, rheumatoid arthritis, AIDS, type 1 diabetes&#xD;
&#xD;
          -  Drugs affecting muscle mass (e.g. steroids)&#xD;
&#xD;
          -  Condition (clinical or EKG) significantly affecting physical capacities and/or&#xD;
             contra-indicating resistance training&#xD;
&#xD;
          -  Habitual practice of resistance training&#xD;
&#xD;
          -  Habitual intake of nutritional supplements&#xD;
&#xD;
          -  Known coagulation disorders (for muscle biopsy)&#xD;
&#xD;
          -  Known allergy to lidocaine (for muscle biopsy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Schneider, PU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of gastroenterology, Department of Gerontology</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>February 20, 2012</last_update_submitted>
  <last_update_submitted_qc>February 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>elderly</keyword>
  <keyword>resistance training</keyword>
  <keyword>oral nutritional supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

